- Home
- Publications
- Publication Search
- Publication Details
Title
DNA damage response inhibitors: An avenue for TNBC treatment
Authors
Keywords
-
Journal
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
Volume 1875, Issue 2, Pages 188521
Publisher
Elsevier BV
Online
2021-02-06
DOI
10.1016/j.bbcan.2021.188521
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial
- (2020) Panagiotis A Konstantinopoulos et al. LANCET ONCOLOGY
- Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
- (2020) Susan M Domchek et al. LANCET ONCOLOGY
- Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer
- (2020) Dong-Hyeon Ha et al. Scientific Reports
- PTEN and DNA-PK determine sensitivity and recovery in response to WEE1 inhibition in human breast cancer
- (2020) Andrä Brunner et al. eLife
- 176P Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332)
- (2020) J. Hauke et al. ANNALS OF ONCOLOGY
- Combination of Olaparib and Radiation Therapy for Triple Negative Breast Cancer: Preliminary Results of the RADIOPARP Phase 1 Trial
- (2020) Pierre Loap et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types
- (2019) Patrick H. Dinkelborg et al. BREAST CANCER RESEARCH AND TREATMENT
- Prevalence and characterization of ATM germline mutations in Chinese BRCA1/2-negative breast cancer patients
- (2019) Ziguo Yang et al. BREAST CANCER RESEARCH AND TREATMENT
- Exploring and comparing adverse events between PARP inhibitors
- (2019) Christopher J LaFargue et al. LANCET ONCOLOGY
- Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis
- (2019) Amirali B. Bukhari et al. JOURNAL OF CLINICAL INVESTIGATION
- A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes
- (2019) Kan Yonemori et al. EUROPEAN JOURNAL OF CANCER
- OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
- (2019) M E Robson et al. ANNALS OF ONCOLOGY
- Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand
- (2019) Lin Mei et al. Journal of Hematology & Oncology
- A novel UCHL3 inhibitor, perifosine, enhances PARP inhibitor cytotoxicity through inhibition of homologous recombination-mediated DNA double strand break repair
- (2019) Zhiwang Song et al. Cell Death & Disease
- Homologous recombination deficiency in triple negative breast cancer
- (2019) Carmen Belli et al. BREAST
- Defining and Modulating ‘BRCAness’
- (2019) Andrea K. Byrum et al. TRENDS IN CELL BIOLOGY
- Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
- (2019) Shaveta Vinayak et al. JAMA Oncology
- A Review of the Hereditary Component of Triple Negative Breast Cancer: High- and Moderate-Penetrance Breast Cancer Genes, Low-Penetrance Loci, and the Role of Nontraditional Genetic Elements
- (2019) Darrell L. Ellsworth et al. Journal of Oncology
- Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant
- (2019) Jennifer K. Litton et al. JOURNAL OF CLINICAL ONCOLOGY
- Induction of BRCAness in Triple-Negative Breast Cancer by a CDK12/13 Inhibitor Improves Chemotherapy
- (2019) Jessica L. Hopkins et al. CANCER CELL
- Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer
- (2019) Victor Quereda et al. CANCER CELL
- Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy
- (2018) Nouf Al-Subhi et al. BREAST CANCER RESEARCH AND TREATMENT
- Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer
- (2018) M. L. Telli et al. BREAST CANCER RESEARCH AND TREATMENT
- Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma
- (2018) David S. Hong et al. CLINICAL CANCER RESEARCH
- Update on PARP Inhibitors in Breast Cancer
- (2018) Alexandra S. Zimmer et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study
- (2018) Jung-Min Lee et al. LANCET ONCOLOGY
- Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
- (2018) Sibylle Loibl et al. LANCET ONCOLOGY
- ATR/CHK1 inhibitors and cancer therapy
- (2018) Zhaojun Qiu et al. RADIOTHERAPY AND ONCOLOGY
- Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer
- (2018) Agnieszka K. Witkiewicz et al. Cell Reports
- Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer
- (2018) Jeff C. Liu et al. Cell Reports
- Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
- (2018) Juan Jin et al. NEOPLASIA
- BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy
- (2018) C. Mio et al. INTERNATIONAL JOURNAL OF CANCER
- ATR inhibition is a promising radiosensitizing strategy for triple negative breast cancer
- (2018) Xinyi Tu et al. MOLECULAR CANCER THERAPEUTICS
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- MicroRNAs and DNA-Damaging Drugs in Breast Cancer: Strength in Numbers
- (2018) Ilaria Plantamura et al. Frontiers in Oncology
- Talazoparib: First Global Approval
- (2018) Sheridan M. Hoy DRUGS
- Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers
- (2018) Tian Tian et al. HUMAN PATHOLOGY
- A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel inBRCA1/2metastatic breast cancer: design and rationale
- (2017) Steven J Isakoff et al. Future Oncology
- Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer
- (2017) Robert W Mutter et al. JOURNAL OF PATHOLOGY
- Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
- (2017) Carsten Denkert et al. LANCET
- Coupling of Homologous Recombination and the Checkpoint by ATR
- (2017) Rémi Buisson et al. MOLECULAR CELL
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells
- (2017) Cyril Ronco et al. MedChemComm
- Targeting the ATR-CHK1 Axis in Cancer Therapy
- (2017) Stuart Rundle et al. Cancers
- Impact of BRCA Mutation Status on Survival of Women With Triple-negative Breast Cancer
- (2017) Siddhartha Yadav et al. Clinical Breast Cancer
- WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance
- (2017) Hongping Zheng et al. Scientific Reports
- A phase II study of the cell cycle checkpoint kinases 1 and 2 (CHK1/2) inhibitor (LY2606368; prexasertib) in sporadic triple negative breast cancer (TNBC)
- (2016) F. Karzai et al. ANNALS OF ONCOLOGY
- 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells
- (2016) Ruoxi Hong et al. BMC CANCER
- RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer
- (2016) Yajing Liu et al. CLINICAL CANCER RESEARCH
- Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors
- (2016) Jeffrey R. Infante et al. CLINICAL CANCER RESEARCH
- Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers
- (2016) T.A. Yap et al. EUROPEAN JOURNAL OF CANCER
- Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer
- (2016) Shivaani Kummar et al. INVESTIGATIONAL NEW DRUGS
- Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
- (2016) Roberta Visconti et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei
- (2016) Magnus T. Dillon et al. MOLECULAR CANCER THERAPEUTICS
- Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
- (2016) Hope S. Rugo et al. NEW ENGLAND JOURNAL OF MEDICINE
- RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy
- (2016) Adrian P. Wiegmans et al. Oncotarget
- DNA Damage in Cancer Therapeutics: A Boon or a Curse?
- (2015) Anchit Khanna CANCER RESEARCH
- mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer
- (2015) W. Mo et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Targeting ATR in Cancer Therapy
- (2015) L. M. Karnitz et al. CLINICAL CANCER RESEARCH
- Synthesis, molecular modeling, and biological evaluation of novel RAD51 inhibitors
- (2015) Jiewen Zhu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer
- (2015) Fergus J. Couch et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors
- (2015) Khanh Do et al. JOURNAL OF CLINICAL ONCOLOGY
- Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition
- (2015) A. P. Wiegmans et al. MOLECULAR CANCER THERAPEUTICS
- Rad51 supports triple negative breast cancer metastasis.
- (2015) Adrian P. Wiegmans et al. Oncotarget
- Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
- (2014) Christopher Bryant et al. BMC CANCER
- Chk1 as a new therapeutic target in triple-negative breast cancer
- (2014) Laurence Albiges et al. BREAST
- DNA single-strand break repair
- (2014) Keith W. Caldecott EXPERIMENTAL CELL RESEARCH
- Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer
- (2014) Tarek M.A. Abdel-Fatah et al. Molecular Oncology
- Targeting triple negative breast cancer: Is p53 the answer?
- (2013) Natalie Turner et al. CANCER TREATMENT REVIEWS
- Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy
- (2013) A. D. Guertin et al. MOLECULAR CANCER THERAPEUTICS
- Triple Negative Breast Cancers Have a Reduced Expression of DNA Repair Genes
- (2013) Enilze Ribeiro et al. PLoS One
- A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer
- (2012) Cynthia X. Ma et al. BREAST CANCER RESEARCH AND TREATMENT
- Chk’ing p53-deficient breast cancers
- (2012) David W. Schoppy et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models
- (2012) Cynthia X. Ma et al. JOURNAL OF CLINICAL INVESTIGATION
- The clonal and mutational evolution spectrum of primary triple-negative breast cancers
- (2012) Sohrab P. Shah et al. NATURE
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
- (2012) Marieke Aarts et al. Cancer Discovery
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
- (2012) Ashish Juvekar et al. Cancer Discovery
- PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy
- (2011) Pawel Domagala et al. BREAST CANCER RESEARCH AND TREATMENT
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations
- (2011) Luis I Toledo et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma
- (2011) K. A. Cole et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features
- (2010) Gulnur Guler et al. BREAST CANCER RESEARCH AND TREATMENT
- A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies
- (2010) Paula M. Fracasso et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome
- (2009) Lyndsay M. Murrow et al. BREAST CANCER RESEARCH AND TREATMENT
- A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
- (2008) Nicholas C Turner et al. EMBO JOURNAL
- Clinical and Pathologic Characteristics of Patients WithBRCA-Positive andBRCA-Negative Breast Cancer
- (2008) Deann P. Atchley et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started